National Rx Drug Abuse & Heroin Summit

National Rx Drug Abuse & Heroin Summit
Name	National Rx Drug Abuse & Heroin Summit
Abbreviation	NRxDH Summit
Formation	2012
Type	Conference
Headquarters	Atlanta, Georgia

Contents

National Rx Drug Abuse & Heroin Summit The National Rx Drug Abuse & Heroin Summit is a recurring professional conference convening policymakers, clinicians, law enforcement, researchers, and advocates focused on pharmaceutical opioid misuse and heroin. It assembles representatives from agencies such as the Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration, and Drug Enforcement Administration alongside academic institutions like Johns Hopkins University, Columbia University, and University of California, San Francisco to share data, policy, and clinical practice. The Summit attracts participants from federal entities including the Department of Health and Human Services, National Institutes of Health, and international organizations such as the World Health Organization.

Overview

The Summit functions as a platform linking stakeholders from American Medical Association, American Society of Addiction Medicine, National Institute on Drug Abuse, Office of National Drug Control Policy, and Food and Drug Administration to discuss interventions, surveillance, and law enforcement strategies. Regular presenters include representatives from Harvard Medical School, Yale School of Medicine, Stanford University School of Medicine, and Mayo Clinic who report on clinical trials, epidemiology, and harm reduction. Nongovernmental participants have included Harm Reduction Coalition, Law Enforcement Action Partnership, Partnership to End Addiction, and advocacy groups such as Shatterproof and Faces & Voices of Recovery. The Summit integrates sessions relevant to healthcare systems like Kaiser Permanente, insurers such as Blue Cross Blue Shield Association, and technology partners including IBM and Google for data analytics.

The Summit was founded amid rising attention to prescription opioid misuse in the 2000s, coinciding with reports from Centers for Disease Control and Prevention and analysis by JAMA and The New England Journal of Medicine authors from institutions like University of Pennsylvania and University of Michigan. Early organizers engaged stakeholders from American Pharmacists Association, American Dental Association, and law enforcement groups including the International Association of Chiefs of Police and the National Sheriffs' Association. Over time, the Summit featured policy addresses linked to initiatives from the White House and briefings connected to legislation such as the Comprehensive Addiction and Recovery Act and the SUPPORT for Patients and Communities Act. The event’s trajectory paralleled research from centers like RAND Corporation, Brookings Institution, and Pew Charitable Trusts analyzing opioid prescribing, overdose mortality, and treatment access.

The Summit highlights initiatives such as expansion of medication-assisted treatment models promoted by Substance Abuse and Mental Health Services Administration and National Institute on Drug Abuse, naloxone distribution campaigns involving American Red Cross and March of Dimes affiliates, and prescription monitoring program integration efforts linked with National Association of Boards of Pharmacy and state health departments. Training initiatives have partnered with professional bodies like American Academy of Family Physicians, American College of Physicians, and Society of General Internal Medicine, while workforce development drew support from Health Resources and Services Administration and academic training programs at Columbia University Mailman School of Public Health. The Summit also spotlights criminal justice diversion programs coordinated with Bureau of Justice Assistance, National Institute of Justice, and local prosecutor offices.

Sponsors and partners have included corporations and foundations such as Mallinckrodt Pharmaceuticals, Purdue Pharma-adjacent stakeholders in early years, and later collaborations with medical device firms like West Pharmaceutical Services and analytics companies such as SAS Institute. Partnerships extend to professional associations including American Nurses Association, American Psychiatric Association, Association for Behavioral Health and Wellness, and nonprofit funders like The Pew Charitable Trusts and Commonwealth Fund. Law enforcement partnerships have involved Federal Bureau of Investigation, United States Marshals Service, and state police organizations, while community-level engagement has involved entities like United Way chapters and local health coalitions.

The Summit has influenced policy dialogue, clinical practice guidelines, and cross-sector collaboration, reflected in citations by Centers for Disease Control and Prevention guidance, National Institutes of Health funding priorities, and academic publications in Addiction and American Journal of Public Health. Critics have raised concerns about sponsorship ties to pharmaceutical companies and potential conflicts echoed in reporting by The New York Times, The Washington Post, and investigations by ProPublica and Reuters. Debates have involved perspectives from Drug Policy Alliance, American Civil Liberties Union, and harm reduction advocates, and legal scrutiny linked to lawsuits such as multidistrict litigation against opioid manufacturers adjudicated in courts including the United States District Court for the Northern District of Ohio and appeals in the United States Court of Appeals for the Sixth Circuit. The Summit continues to adapt amid shifting federal policies, state legislation, and scientific findings from institutions like NIH Clinical Center and international surveillance from European Monitoring Centre for Drugs and Drug Addiction.

Category:Conferences in the United States